Journal of Clinical Medicine (Apr 2020)

Clinical Evidence for Q10 Coenzyme Supplementation in Heart Failure: From Energetics to Functional Improvement

  • Anna Di Lorenzo,
  • Gabriella Iannuzzo,
  • Alessandro Parlato,
  • Gianluigi Cuomo,
  • Crescenzo Testa,
  • Marta Coppola,
  • Giuseppe D’Ambrosio,
  • Domenico Alessandro Oliviero,
  • Silvia Sarullo,
  • Giuseppe Vitale,
  • Cinzia Nugara,
  • Filippo M. Sarullo,
  • Francesco Giallauria

DOI
https://doi.org/10.3390/jcm9051266
Journal volume & issue
Vol. 9, no. 5
p. 1266

Abstract

Read online

Oxidative stress and mitochondrial dysfunction are hallmarks of heart failure (HF). Coenzyme Q10 (CoQ10) is a vitamin-like organic compound widely expressed in humans as ubiquinol (reduced form) and ubiquinone (oxidized form). CoQ10 plays a key role in electron transport in oxidative phosphorylation of mitochondria. CoQ10 acts as a potent antioxidant, membrane stabilizer and cofactor in the production of adenosine triphosphate by oxidative phosphorylation, inhibiting the oxidation of proteins and DNA. Patients with HF showed CoQ10 deficiency; therefore, a number of clinical trials investigating the effects of CoQ10 supplementation in HF have been conducted. CoQ10 supplementation may confer potential prognostic advantages in HF patients with no adverse hemodynamic profile or safety issues. The latest evidence on the clinical effects of CoQ10 supplementation in HF was reviewed.

Keywords